Literature DB >> 10769007

Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors.

P Vukovic1, P M Hogarth, N Barnes, D C Kaslow, M F Good.   

Abstract

Merozoite surface protein 1 (MSP-1(19)) is a leading malaria vaccine candidate. Specific antibodies contribute to immunity; binding to macrophages is believed to represent the main action of malaria antibodies. We show that an MSP-1(19)-specific immunoglobulin G3 (IgG3) monoclonal antibody can passively transfer protection to mice deficient in the alpha chain of Fc-gammaRI whose macrophages cannot bind IgG3.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10769007      PMCID： PMC97522          DOI： 10.1128/IAI.68.5.3019-3022.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  19 in total

1.  Mechanisms of action of hyperimmune serum in mediating protective immunity to rodent malaria (Plasmodium berghei).

Authors:  T C Quinn; D J Wyler
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

2.  FcR gamma chain deletion results in pleiotrophic effector cell defects.

Authors:  T Takai; M Li; D Sylvestre; R Clynes; J V Ravetch
Journal:  Cell       Date:  1994-02-11       Impact factor: 41.582

3.  A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

Review 4.  Mechanisms of defense against P. falciparum asexual blood stages in humans.

Authors:  P Druilhe; J L Pérignon
Journal:  Immunol Lett       Date:  1994-07       Impact factor: 3.685

5.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

Authors:  J A Stoute; M Slaoui; D G Heppner; P Momin; K E Kester; P Desmons; B T Wellde; N Garçon; U Krzych; M Marchand
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

6.  Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine.

Authors:  J H Tian; L H Miller; D C Kaslow; J Ahlers; M F Good; D W Alling; J A Berzofsky; S Kumar
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

7.  Monoclonal antibodies against a specific surface determinant on malarial (Plasmodium knowlesi) merozoites block erythrocyte invasion.

Authors:  N Epstein; L H Miller; D C Kaushel; I J Udeinya; J Rener; R J Howard; R Asofsky; M Aikawa; R L Hess
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

8.  Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

Authors:  S Kumar; A Yadava; D B Keister; J H Tian; M Ohl; K A Perdue-Greenfield; L H Miller; D C Kaslow
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

9.  Immunization against malaria with a recombinant protein.

Authors:  I T Ling; S A Ogun; A A Holder
Journal:  Parasite Immunol       Date:  1994-02       Impact factor: 2.280

10.  Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

Authors:  M J Blackman; T J Scott-Finnigan; S Shai; A A Holder
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307
View more
  12 in total

1.  Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.

Authors:  Mark Nagata; Teri Wong; David Clements; George Hui
Journal:  Exp Parasitol       Date:  2006-11-21       Impact factor: 2.011

2.  Integrin β1 Promotes the Interaction of Murine IgG3 with Effector Cells.

Authors:  Carolyn Saylor Hawk; Carolina Coelho; Diane Sthefany Lima de Oliveira; Verenice Paredes; Patrícia Albuquerque; Anamélia Lorenzetti Bocca; Ananésia Correa Dos Santos; Victoria Rusakova; Heather Holemon; Ildinete Silva-Pereira; Maria Sueli Soares Felipe; Hideo Yagita; André Moraes Nicola; Arturo Casadevall
Journal:  J Immunol       Date:  2019-03-20       Impact factor: 5.422

3.  Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.

Authors:  T Scorza; K Grubb; P Smooker; A Rainczuk; D Proll; T W Spithill
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

4.  Different regions of the malaria merozoite surface protein 1 of Plasmodium chabaudi elicit distinct T-cell and antibody isotype responses.

Authors:  S J Quin; J Langhorne
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

Authors:  James M Burns; Patrick R Flaherty; Payal Nanavati; William P Weidanz
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii.

Authors:  Irosoki Eslava; Gilberto Payares; Beatriz M Pernia; Anthony A Holder; Lilian M Spencer
Journal:  Malar J       Date:  2010-02-10       Impact factor: 2.979

Review 7.  Fc-receptors and immunity to malaria: from models to vaccines.

Authors:  R J Pleass
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

8.  Antibodies generated against conserved antigens expressed by bacteria and allergen-bearing fungi suppress airway disease.

Authors:  Nicholas W Kin; Emily K Stefanov; Brian L P Dizon; John F Kearney
Journal:  J Immunol       Date:  2012-07-25       Impact factor: 5.422

9.  Humoral responses against the C-terminal region of merozoite surface protein 1 can be remembered for more than 30 years in persons exposed to Plasmodium vivax.

Authors:  Kook Jin Lim; Jea Won Park; Joon-Sup Yeom; Young-Ha Lee; Seung Bum Yoo; Jae Hoon Oh; Mi Jin Sohn; Young Yil Bahk; Yu Sam Kim
Journal:  Parasitol Res       Date:  2004-01-27       Impact factor: 2.289

10.  Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.

Authors:  E Elsa Herdiana Murhandarwati; Lina Wang; Harini D de Silva; Charles Ma; Magdalena Plebanski; Casilda G Black; Ross L Coppel
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.